Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Irene M. Ghobrial; Ashraf Z Badros; James J. Vredenburgh; Jeffrey Matous; Aaron M. Caola; Alexandra Savell; Patrick Henrick; Claudia E. Paba-Prada; Robert L. Schlossman; Jacob P. Laubach; Jacalyn Rosenblatt; Andrew Yee; Jeffrey S. Wisch; Charles M. Farber; Rodrigo O. Maegawa; Saad Z Usmani; Joseph Cappuccio; Bradley Rivotto; Kimberly Noonan; Kaitlen Reyes; Nikhil C. Munshi; Kenneth C. Anderson; Paul Richardson

doi:10.1182/BLOOD.V128.22.976.976

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Irene M. Ghobrial
, Ashraf Z Badros
, James J. Vredenburgh
, Jeffrey Matous
, Aaron M. Caola
, Alexandra Savell
, Patrick Henrick
, Claudia E. Paba-Prada
, Robert L. Schlossman
, Jacob P. Laubach
, Jacalyn Rosenblatt
, Andrew Yee
, Jeffrey S. Wisch
, Charles M. Farber
, Rodrigo O. Maegawa
, Saad Z Usmani
, Joseph Cappuccio
, Bradley Rivotto
, Kimberly Noonan
, Kaitlen Reyes

Nikhil C. Munshi, Kenneth C. Anderson, Paul Richardson

Harvard University
University of Maryland, Baltimore
Department of Oncology, St. Francis Hospital and Medical Center, Hartford, CT
Colorado Blood Cancer Institute, Denver, CO
Beth Israel Deaconess Medical Center
Newton Wellesley Hospital
Morristown Medical Center
Cancer Care of Maine, Brewer, ME
Carolinas Healthcare System

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	128
Issue number	22
DOIs	https://doi.org/10.1182/BLOOD.V128.22.976.976
State	Published - Nov 29 2018
Externally published	Yes

Disciplines

Immunology and Infectious Disease
Medicine and Health Sciences
Internal Medicine

Access to Document

10.1182/BLOOD.V128.22.976.976License: Unspecified

Cite this

Ghobrial, I. M., Badros, A. Z., Vredenburgh, J. J., Matous, J., Caola, A. M., Savell, A., Henrick, P., Paba-Prada, C. E., Schlossman, R. L., Laubach, J. P., Rosenblatt, J., Yee, A., Wisch, J. S., Farber, C. M., Maegawa, R. O., Usmani, S. Z., Cappuccio, J., Rivotto, B., Noonan, K., ... Richardson, P. (2018). Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 128(22). https://doi.org/10.1182/BLOOD.V128.22.976.976

Ghobrial, IM, Badros, AZ, Vredenburgh, JJ, Matous, J, Caola, AM, Savell, A, Henrick, P, Paba-Prada, CE, Schlossman, RL, Laubach, JP, Rosenblatt, J, Yee, A, Wisch, JS, Farber, CM, Maegawa, RO, Usmani, SZ, Cappuccio, J, Rivotto, B, Noonan, K, Reyes, K, Munshi, NC, Anderson, KC & Richardson, P 2018, 'Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma', Blood, vol. 128, no. 22. https://doi.org/10.1182/BLOOD.V128.22.976.976

@article{bb21383c8ad54519908680edb9826b6d,

title = "Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma",

author = "Ghobrial, \{Irene M.\} and Badros, \{Ashraf Z\} and Vredenburgh, \{James J.\} and Jeffrey Matous and Caola, \{Aaron M.\} and Alexandra Savell and Patrick Henrick and Paba-Prada, \{Claudia E.\} and Schlossman, \{Robert L.\} and Laubach, \{Jacob P.\} and Jacalyn Rosenblatt and Andrew Yee and Wisch, \{Jeffrey S.\} and Farber, \{Charles M.\} and Maegawa, \{Rodrigo O.\} and Usmani, \{Saad Z\} and Joseph Cappuccio and Bradley Rivotto and Kimberly Noonan and Kaitlen Reyes and Munshi, \{Nikhil C.\} and Anderson, \{Kenneth C.\} and Paul Richardson",

year = "2018",

month = nov,

day = "29",

doi = "10.1182/BLOOD.V128.22.976.976",

language = "American English",

volume = "128",

journal = "Blood",

publisher = "American Society of Hematology",

number = "22",

}

TY - JOUR

T1 - Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

AU - Ghobrial, Irene M.

AU - Badros, Ashraf Z

AU - Vredenburgh, James J.

AU - Matous, Jeffrey

AU - Caola, Aaron M.

AU - Savell, Alexandra

AU - Henrick, Patrick

AU - Paba-Prada, Claudia E.

AU - Schlossman, Robert L.

AU - Laubach, Jacob P.

AU - Rosenblatt, Jacalyn

AU - Yee, Andrew

AU - Wisch, Jeffrey S.

AU - Farber, Charles M.

AU - Maegawa, Rodrigo O.

AU - Usmani, Saad Z

AU - Cappuccio, Joseph

AU - Rivotto, Bradley

AU - Noonan, Kimberly

AU - Reyes, Kaitlen

AU - Munshi, Nikhil C.

AU - Anderson, Kenneth C.

AU - Richardson, Paul

PY - 2018/11/29

Y1 - 2018/11/29

UR - https://ash.confex.com/ash/2018/webprogram/Paper117914.html

U2 - 10.1182/BLOOD.V128.22.976.976

DO - 10.1182/BLOOD.V128.22.976.976

M3 - Article

VL - 128

JO - Blood

JF - Blood

IS - 22

ER -

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Disciplines

Access to Document

Other files and links

Cite this